Detalles de la búsqueda
1.
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Gynecol Oncol
; 166(2): 254-262, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35718565
2.
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Int J Gynecol Cancer
; 32(6): 761-768, 2022 06 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35086926
3.
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
Int J Gynecol Cancer
; 31(1): 134-138, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33097567
4.
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
Lancet Oncol
; 20(9): 1273-1285, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31345626
5.
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gynecol Oncol
; 153(3): 541-548, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31005287
6.
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol
; 19(3): 295-309, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29449189
7.
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
Qual Life Res
; 27(1): 59-74, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29248998
8.
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Oncologist
; 22(9): 1117-1124, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28596446
9.
Cytokine (IL16) and tyrphostin actions on ovarian primordial follicle development.
Reproduction
; 148(3): 321-31, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24970835
10.
Right-sided weakness in a Rwandan patient with untreated Tetralogy of Fallot.
Int J Emerg Med
; 16(1): 19, 2023 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36918806
11.
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.
Int J Radiat Oncol Biol Phys
; 109(4): 975-986, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33129910
12.
Epigenetics and transgenerational inheritance in domesticated farm animals.
J Anim Sci Biotechnol
; 5(1): 48, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25810901
Resultados
1 -
12
de 12
1
Próxima >
>>